Olpasiran is an investigational medication designed to reduce levels of lipoprotein(a), also known as Lp(a), in the blood. This medication is being studied to prevent first major cardiovascular events in people who have high levels of lipoprotein(a). Olpasiran works by targeting and reducing the production of lipoprotein(a), which is a type of fat-protein particle that can contribute to heart disease when present in elevated amounts.

The trial also includes a placebo, which is not an active medication but is used as a comparison to evaluate the effectiveness of olpasiran.

Coronary Heart Disease – A condition where the heart’s blood vessels become narrowed or blocked by fatty deposits called plaques. This process develops gradually over many years as cholesterol and other substances build up on the artery walls. The reduced blood flow can cause chest pain and shortness of breath during physical activity.

Myocardial Infarction – Also known as a heart attack, it occurs when blood flow to a part of the heart muscle becomes blocked. The blockage is usually caused by a buildup of fatty deposits in the coronary arteries that suddenly ruptures and forms a clot. This leads to damage or death of the affected heart muscle tissue.

Ischemic Stroke – A condition that occurs when blood flow to the brain is blocked by a clot in a blood vessel. The blockage prevents brain cells from receiving oxygen and nutrients they need. This type of stroke develops suddenly and affects specific areas of the brain depending on which blood vessel is blocked.

Cardiovascular Disease – A broad term for conditions affecting the heart and blood vessels throughout the body. It develops when arteries become stiff and narrow, making it harder for blood to flow freely. The condition typically progresses slowly over many years and can affect different parts of the circulatory system.